Tenet Healthcare Corp (NYSE:THC) – Investigation analysts at Piper Jaffray Firms lowered their Q2 2019 EPS estimates for shares of Tenet Healthcare in a study note issued to investors on Tuesday, April 30th, Zacks Investment Investigation reports. Piper Jaffray Firms analyst S. James now anticipates that the organization will earn $.42 per share for the quarter, down from their preceding estimate of $.63. Piper Jaffray Firms also issued estimates for Tenet Healthcare’s Q3 2019 earnings at $.52 EPS, FY2019 earnings at $two.43 EPS, Q1 2020 earnings at $.27 EPS, Q2 2020 earnings at $.47 EPS, Q3 2020 earnings at $.42 EPS and FY2020 earnings at $1.91 EPS.
Tenet Healthcare (NYSE:THC) final announced its earnings outcomes on Monday, April 29th. The organization reported $.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $.29 by $.25. The organization had income of $four.55 billion in the course of the quarter, compared to the consensus estimate of $four.51 billion. Tenet Healthcare had a damaging net margin of .04% and a constructive return on equity of 29.29%. The firm’s income for the quarter was down three.three% on a year-more than-year basis. For the duration of the very same quarter in the prior year, the organization posted $.57 earnings per share.
Other analysts also lately issued study reports about the stock. Raymond James improved their target price tag on shares of Tenet Healthcare from $37.00 to $47.00 in a report on Wednesday, February 27th. Citigroup improved their target price tag on shares of Tenet Healthcare from $35.00 to $37.00 and gave the organization a “buy” rating in a report on Wednesday, February 27th. Mizuho restated a “buy” rating and set a $28.00 price tag objective on shares of Tenet Healthcare in a report on Monday, January 28th. TheStreet downgraded shares of Tenet Healthcare from a “c” rating to a “d+” rating in a report on Monday, Could 13th. Ultimately, Barclays set a $24.00 price tag objective on shares of Tenet Healthcare and gave the stock a “hold” rating in a report on Wednesday, April 17th. Two study analysts have rated the stock with a sell rating, ten have issued a hold rating and 3 have issued a get rating to the organization. Tenet Healthcare presently has an typical rating of “Hold” and a consensus price tag target of $30.07.
Shares of THC stock opened at $20.84 on Friday. The stock has a industry capitalization of $two.15 billion, a PE ratio of 11.20, a PEG ratio of .38 and a beta of 1.68. The organization has a debt-to-equity ratio of 21.98, a present ratio of 1.23 and a fast ratio of 1.15. Tenet Healthcare has a a single year low of $16.60 and a a single year higher of $39.74.
Institutional investors and hedge funds have lately purchased and sold shares of the organization. Oregon Public Staff Retirement Fund improved its stake in shares of Tenet Healthcare by 1,653.four% in the fourth quarter. Oregon Public Staff Retirement Fund now owns 565,569 shares of the company’s stock worth $33,00 just after buying an further 533,313 shares in the final quarter. Enlightenment Investigation LLC bought a new position in shares of Tenet Healthcare in the fourth quarter worth about $36,00. PNC Economic Solutions Group Inc. improved its stake in shares of Tenet Healthcare by 101.9% in the 1st quarter. PNC Economic Solutions Group Inc. now owns 1,351 shares of the company’s stock worth $38,00 just after buying an further 682 shares in the final quarter. Pearl River Capital LLC bought a new position in shares of Tenet Healthcare in the fourth quarter worth about $41,00. Ultimately, Economic Gravity Wealth Inc. bought a new position in shares of Tenet Healthcare in the 1st quarter worth about $51,00.
About Tenet Healthcare
Tenet Healthcare Corporation operates as a diversified healthcare solutions organization. The organization operates in 3 segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its basic hospitals present acute care solutions, operating and recovery rooms, radiology and respiratory therapy solutions, clinical laboratories, and pharmacies.
Featured Story: Technical Evaluation
Get a no cost copy of the Zacks study report on Tenet Healthcare (THC)
For far more details about study offerings from Zacks Investment Investigation, check out Zacks.com
Acquire News & Ratings for Tenet Healthcare Each day – Enter your e-mail address under to acquire a concise every day summary of the most recent news and analysts’ ratings for Tenet Healthcare and associated firms with MarketBeat.com’s Absolutely free every day e-mail newsletter.